Intranasal, rapid-acting vaccine for all seasonal and pandemic influenza viruses

HORIZON.2.1HORIZON-RIAID: 101080692
EC Contribution
โ‚ฌ75,678
Consortium Size
8 orgs
โ–ถSummary

Researchers worldwide have been working to develop a universal flu vaccine, but no breakthrough has yet been achieved. FLUniversal is not ""another costly universal flu project"". It is an opportunity to create a genuine universal flu vaccine that will set the standard for rapid, efficient vaccine development, and generate know-how and tools to develop next-generation vaccines. We plan to exploit our increased understanding of molecular mechanisms of influenza infection and immunity to develop a vaccine effective against all flu virus strains. Our innovation uses genetically modified flu strains administered intranasally in a prime-boost regimen. This approach rapidly induces interferon and broadly cross-neutralising antibodies in the nasal passages and a systemic immune response directed to the conserved HA stalk. Proof of concept for universal protection was demonstrated in the ferret

Consortium (8)

Project Results (4)

Source: CORDIS, the EU research results database.

โ–ถPublications (1)
Development of an intranasal, universal influenza vaccine in an EU-funded public-private partnership: the FLUniversal consortium
Frontiers in Immunologyยท 2025DOI
Victor M. Cnossen, Paula C. Leao Moreira, Othmar G. Engelhardt, Jerzy Samolej, Geert H. Groeneveld, Simon P. Jochems, Wesley Huisman, Gabriel K. Pedersen, Katharina Wรธrzner, Lukas Recek, Giulia Piccini, Claudia M. Trombetta, Amy Aspelund, Alaura Hoag, Manfred Reiter, Carrie Wick, Thomas Muster, Ingrid Maria Catharina Kamerling
โ–ถDeliverables (2)
Data Management Plan
Websites, patent fillings, videos etc.
โ–ถOther Results (1)
Periodic Reporting for period 1 - FLUniversal (Intranasal, rapid-acting vaccine for all seasonal and pandemic influenza viruses)